Information  X 
Enter a valid email address

Abzena PLC (ABZA)

  Print      Mail a friend

Thursday 14 September, 2017

Abzena PLC

Result of AGM

RNS Number : 7821Q
Abzena PLC
14 September 2017
 

Abzena plc

 

Result of Annual General Meeting

 

Cambridge, UK, 14 September 2017: Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable better biopharmaceutical products, announces that at its Annual General Meeting held today at 10am on the Babraham Research Campus in Cambridge, all resolutions were duly passed on a show of hands.

 

Details of the votes received in relation to each of the resolutions (which are more particularly described in the Notice of Annual General Meeting dated 28 July 2017) are as follows:

 

Resol

 

Vote For

% In favour

Votes Against

% Against

Votes Abstain

% Abstain

Total Votes

1

153,588,233

100

0

0

0

0

153,588,233

2

153,588,233

100

0

0

0

0

153,588,233

3

153,588,233

100

0

0

0

0

153,588,233

4

153,588,233

100

0

0

0

0

153,588,233

5

153,588,233

100

0

0

0

0

153,588,233

6

153,588,233

100

0

0

0

0

153,588,233

7

153,588,233

100

0

0

0

0

153,588,233

8

153,588,233

100

0

0

0

0

153,588,233

Percentage figures have been subject to rounding as considered appropriate.

 

The total number of ordinary shares of £0.002 each eligible to be voted at the Annual General Meeting was 213,639,236.

 

Enquiries:

 

Abzena plc

John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer

 

+44 1223 903498

Numis (Nominated Adviser and Broker)

Clare Terlouw / James Black / Paul Gillam

 

+44 20 7260 1000

 

 

N+1 Singer (Joint Broker)

Aubrey Powell / Liz Yong

 

+44 20 7496 3000

Instinctif Partners

Melanie Toyne Sewell / Alex Shaw

+44 20 7457 2020

[email protected]

 

 

Notes to Editors

 

About Abzena

 

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

 

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

 

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

·   Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

·   Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

·   Cell line development for the manufacture of recombinant proteins and antibodies;

·   Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

·   Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

·   Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

·   GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please see www.abzena.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSFEFFLFWSELU

a d v e r t i s e m e n t